Detecting mutant KRAS in liquid biopsies : a biomarker searching for a role
No pain, no gain… What we can learn from a trial reporting negative results
Cancer vaccines at the age of immune checkpoint inhibitors : reasonable approach as combination therapy in advanced urothelial carcinoma?
Adjuvant sunitinib in renal cell carcinoma : from evidence to recommendation
Chemotherapy in end-of-life care
More valuable than platinum : first-line pembrolizumab in advanced stage non-small-cell lung cancer
Statistical controversies in clinical research : comparison of primary outcomes in protocols, public clinical-trial registries and publications
Statistical controversies in clinical research : early-phase adaptive design for combination immunotherapies
Fifth Ovarian Cancer Consensus Conference : individualized therapy and patient factors
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup : first-line interventions
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) : clinical trial design for rare ovarian tumours
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup : recurrent disease
Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Nectin-4 : a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer : a multicenter randomized phase III trial
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma
Use of chemotherapy near the end of life : what factors matter?
Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population
Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wildtype stage III colon cancer patients
Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer : do we need to worry?
Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma : results from a prospective, randomized, open-label, crossover study (PrefMab)
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients : analysis of 135 patients from the LYSA group
ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients : a single-center experience
The natural history and patterns of metastases from mucosal melanoma : an analysis of 706 prospectively-followed patients
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer : a phase 1 trial
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma
Adjuvant sunitinib for high-risk-resected renal cell carcinoma : a meta-analysis of ASSURE and S-TRAC trials
Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment
Consideration of an association between performance status and ramucirumab efficacy
Reply to the Letter to the editor ‘Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma : randomized phase II trial’ by Fornaro et al.
Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
Reply to the letter to the editor ‘Integrating communication as a core skill in the global curriculum for medical oncology’ by Horlait et al.
Immune checkpoint inhibitors-related orchitis